Zhejiang Hisun Pharmaceutical has been granted a patent for a pyrimidine derivative represented by formula (I) as a therapeutic agent, particularly as a FGFR4 kinase inhibitor. The method involves administering the compound to treat diseases related to FGFR4 over-expression. GlobalData’s report on Zhejiang Hisun Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Zhejiang Hisun Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zhejiang Hisun Pharmaceutical's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Pyrimidine derivative for treating diseases of fgfr4 over-expression

Source: United States Patent and Trademark Office (USPTO). Credit: Zhejiang Hisun Pharmaceutical Co Ltd

A recently granted patent (Publication Number: US11827625B2) discloses a method for treating diseases associated with FGFR4 over-expression. The method involves administering a compound represented by formula (I) or its derivatives to a patient in need of treatment. The compound can also be a specific compound of formula (II), with various substituents such as halogen or alkoxy (R1), —NHC(O)CH-CH2 (R2), and monospiroheterocyclyl (R3) that can be further substituted by alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl.

Furthermore, the patent claims cover a wide range of possible configurations for R3, including different combinations of 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered monospiroheterocyclyl structures. The compound selection is not limited to a single option, providing flexibility in the choice of the compound for treatment. This patent highlights a specific method for addressing diseases related to FGFR4 over-expression, offering a potential avenue for therapeutic intervention in such conditions.

To know more about GlobalData’s detailed insights on Zhejiang Hisun Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies